https://www.selleckchem.com/pr....oducts/Puromycin-2HC
7 GyRBE, 56.6 GyRBE, and 58.3 GyRBE. Visual decline was only seen in children with primary tumors of the optic pathway or suprasellar region. Visual acuity decline following radiotherapy for intracranial malignancies in children is rare. A dose of approximately 56 GyRBE to 0.1 cm results in an approximately 5% risk of visual acuity decline for children with suprasellar or optic pathway tumors. A dose to 0.1 cm of 56 GyRBE appears to be safe for children with tumors elsewhere in the brain. Visual acuity decline following radiother
Like
Comment
Share
